ELISA
LUÑO FERNANDEZ
Investigador/a
Joan
Bargay Lleonart
Publicaciones en las que colabora con Joan Bargay Lleonart (10)
2018
-
Azacitidine improves outcome in higher-risk MDS patients with chromosome 7 abnormalities: a retrospective comparison of GESMD and GFM registries
British Journal of Haematology, Vol. 181, Núm. 3, pp. 350-359
2016
-
Prognostic impact of chromosomal translocations in myelodysplastic syndromes and chronic myelomonocytic leukemia patients. A study by the spanish group of myelodysplastic syndromes
Genes Chromosomes and Cancer, Vol. 55, Núm. 4, pp. 322-327
2015
-
Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: Results from the Spanish registry
Leukemia, Vol. 29, Núm. 9, pp. 1875-1881
-
Use of newer prognostic indices for patients with myelodysplastic syndromes in the low and intermediate-1 risk categories: A population-based study
The Lancet Haematology, Vol. 2, Núm. 6, pp. e260-e266
2014
-
Multivariate time-dependent comparison of the impact of lenalidomide in lower-risk myelodysplastic syndromes with chromosome 5q deletion
British Journal of Haematology, Vol. 166, Núm. 2, pp. 189-201
-
Results of treatment with azacitidine in patients aged ≥ 75 years included in the Spanish Registry of Myelodysplastic Syndromes
Leukemia and Lymphoma, Vol. 55, Núm. 6, pp. 1300-1303
-
Transfusion dependence development and disease evolution in patients with MDS and del(5q) and without transfusion needs at diagnosis
Leukemia Research, Vol. 38, Núm. 3, pp. 304-309
2013
-
Reciprocal translocations in myelodysplastic syndromes and chronic myelomonocytic leukemias: Review of 5,654 patients with an evaluable karyotype
Genes Chromosomes and Cancer, Vol. 52, Núm. 8, pp. 753-763
2012
-
Prognostic value of trisomy 8 as a single anomaly and the influence of additional cytogenetic aberrations in primary myelodysplastic syndromes
British Journal of Haematology, Vol. 159, Núm. 3, pp. 311-321
2011
-
Evaluation of tolerability and efficacy of imatinib mesylate in elderly patients with chronic phase CML: ELDERGLI study
Leukemia Research, Vol. 35, Núm. 9, pp. 1184-1187